Seagen Inc. Announces Merger with Pfizer Inc. Subject to Regulatory Approvals

Strategic Insights -

Pursuant to a previously disclosed Agreement and Plan of Merger, Seagen Inc. has entered into an agreement with Pfizer Inc. to merge the companies, with Seagen surviving as a wholly-owned subsidiary of Pfizer. The merger is subject to regulatory approvals and clearances in the United States and certain other jurisdictions. Seagen has filed a definitive proxy statement with the Securities and Exchange Commission in connection with the merger, which includes supplemental disclosures regarding regulatory requirements.

Key Takeaways:

  • The merger between Seagen Inc. and Pfizer Inc. is subject to regulatory approvals and clearances in the United States and certain other jurisdictions, including antitrust laws and foreign investment laws.
  • Seagen filed a definitive proxy statement with the Securities and Exchange Commission on April 24, 2023, in connection with the merger, which includes supplemental disclosures regarding regulatory requirements.
  • The completion of the merger is conditioned on approvals and clearances from the European Commission, the United States Federal Trade Commission, and the United States Department of Justice.
  • Seagen and Pfizer filed a Notification and Report Form with the FTC and DOJ on May 12, 2023, as required under the Hart-Scott-Rodino Act.
  • The merger is expected to have significant benefits, including the potential for increased research and development capabilities and expanded market reach.
  • However, the completion of the merger is subject to various uncertainties and risks, including regulatory approval and potential delays.

Statistics:

  • The merger is subject to regulatory approvals and clearances in the United States and certain other jurisdictions.
  • Seagen filed a definitive proxy statement with the SEC on April 24, 2023.
  • The completion of the merger is conditioned on approvals and clearances from the European Commission, the United States Federal Trade Commission, and the United States Department of Justice.
  • Seagen and Pfizer received a filing date of May 12, 2023, for a Notification and Report Form with the FTC and DOJ.
  • The merger is subject to various uncertainties and risks, including regulatory approval and potential delays.

Sources:

  • Seagen Inc.'s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 24, 2023.
  • Hart-Scott-Rodino Act notification and report form filed by Seagen and Pfizer with the United States Federal Trade Commission and the United States Department of Justice on May 12, 2023.